-
Mashup Score: 0FDA Approves Melphalan Injection in Hepatic-Dominant Uveal Melanoma - 8 month(s) ago
Supporting data for the FDA approval of melphalan administered via percutaneous hepatic perfusion for metastatic uveal melanoma come from the phase 3 FOCUS study.
Source: www.cancernetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0IRAK-4 Inhibitor CA-4948 May Enhance Immunotherapeutic Outcomes in Melanoma With Brain Metastases - 12 month(s) ago
Bently Doonan, MD, discusses how CA-4948 can penetrate the blood-brain barrier and interact with the tumor microenvironment, and how this approach may open doors for patients with melanoma who have brain metastases.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The development of the oral, IRAK-4 inhibitor, CA-4948, showed enhanced antitumor activity and efforts are underway to evaluate the agent in combination with pembrolizumab in a first in-human clinical trial. @BentlyMd #melcsm #oncology https://t.co/1HnZIXEqWW
-
-
Mashup Score: 3IRAK-4 Inhibitor CA-4948 May Enhance Immunotherapeutic Outcomes in Melanoma With Brain Metastases - 12 month(s) ago
Bently Doonan, MD, discusses how CA-4948 can penetrate the blood-brain barrier and interact with the tumor microenvironment, and how this approach may open doors for patients with melanoma who have brain metastases.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Bently Doonan, MD, discusses how CA-4948 can penetrate the blood-brain barrier and interact with the tumor microenvironment, and how this approach may open doors for patients with melanoma who have brain metastases. @BentlyMd #melcsm #oncology https://t.co/2dWzK4Hmc4 https://t.co/6J1kN6UAo4
-
-
Mashup Score: 0IRAK-4 Inhibitor CA-4948 May Enhance Immunotherapeutic Outcomes in Melanoma With Brain Metastases - 12 month(s) ago
Bently Doonan, MD, discusses how CA-4948 can penetrate the blood-brain barrier and interact with the tumor microenvironment, and how this approach may open doors for patients with melanoma who have brain metastases.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
IRAK-4 Inhibitor CA-4948 May Enhance Immunotherapeutic Outcomes in Melanoma With Brain Metastases @BentlyMd #melcsm #oncology https://t.co/HekGgGrADo
-
-
Mashup Score: 3Early ctDNA Testing Provides Another Tool for Predicting Survival Outcomes With Tebentafusp in Metastatic Uveal Melanoma - 12 month(s) ago
Ryan J. Sullivan, MD, discusses previous research on tebentafusp in uveal melanoma that led to the inception of the IMCgp100-202 trial and clinical implications for data confirming the predictive value of circulating tumor DNA levels.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Early ctDNA Testing Provides Another Tool for Predicting Survival Outcomes With Tebentafusp in Metastatic Uveal Melanoma @harvardmed @MGHCancerCenter #melcsm https://t.co/HS3tV3L2t0
-
-
Mashup Score: 0FDA Grants Fast Track Designation to KIN-2787 for Select Stage IIB to IV Malignant Melanoma - 1 year(s) ago
The FDA has granted a fast track designation to KIN-2787 for use as a potential therapeutic option in patients with BRAF class II or III alteration–positive and/or NRAS mutation–positive, metastatic or unresectable, stage IIB to IV malignant melanoma.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
.@US_FDA granted a fast track designation to KIN-2787 in patients with BRAF class II or III alteration–positive and/or NRAS mutation–positive, metastatic or unresectable, stage IIB to IV malignant melanoma. @CesarAPerezMD @SarahCannonDocs #melcsm https://t.co/9fY9F1HWdR
-
-
Mashup Score: 0FDA Grants Fast Track Designation to KIN-2787 for Select Stage IIB to IV Malignant Melanoma - 1 year(s) ago
The FDA has granted a fast track designation to KIN-2787 for use as a potential therapeutic option in patients with BRAF class II or III alteration–positive and/or NRAS mutation–positive, metastatic or unresectable, stage IIB to IV malignant melanoma.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In a phase 1 trial, investigators are examining the safety, tolerability, pharmacokinetics, and preliminary efficacy of KIN-2787 in adult patients with BRAF-mutated, advanced or metastatic solid tumors. @US_FDA @CesarAPerezMD @SarahCannonDocs #melcsm https://t.co/l89mv0IFRq https://t.co/UKQmthzEzL
-
-
Mashup Score: 0Artificial Intelligence Predicts Overall Survival in Patients With Advanced Melanoma - 2 year(s) ago
By reading CT scans, machine learning could aid investigators in improving treatment decision making.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
By reading CT scans, machine learning could aid investigators in improving treatment decision making. #melcsm https://t.co/bfcMlRCBsb
-
-
Mashup Score: 4
One of the first “roles” to be questioned was of oncogene-directed therapy in patients with BRAF V600–mutant disease. EA6183 (DREAMseq) studied first-line ipilimumab/nivolumab compared with first-line dabrafenib and trametinib.
Source: ASCO Daily NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Dr. Leslie Fecher of @UMRogelCancer discusses the use of PD-1 plus LAG-3 inhibitor therapy and PD-1 plus CTLA-4 inhibitor therapy in the first-line setting for metastatic #melanoma 💬 https://t.co/wX6xjnZu8P #melcsm
-
-
Mashup Score: 0Early Data for PD-L1/IDO Peptide Vaccine Plus Standard PD-1 Inhibition Shows Promise in Metastatic Melanoma - 2 year(s) ago
Data from a phase 1/2 trial examining nivolumab plus a PD-L1/IDO peptide vaccine indicates early activity in patients with metastatic melanoma, according to results from the 2022 AACR Annual Meeting.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Data from a phase 1/2 trial examining nivolumab plus a PD-L1/IDO peptide vaccine indicates early activity in patients with metastatic melanoma, according to results from the 2022 AACR Annual Meeting. #AACR22 #melcsm | @AACR https://t.co/q0tzWiHycm
-
Supporting data for the @FDA approval of melphalan administered via percutaneous hepatic perfusion for metastatic uveal melanoma come from the phase 3 FOCUS study. @FDAOncology #melcsm https://t.co/yNCT2u61wz